DUBLIN--(http://www.researchandmarkets.com/research/gqkcqw/masitinib) has announced the addition of GlobalData's new report "Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis" to their offering.)--Research and Markets (
“Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis”
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.
AB Science is developing a novel oral c-Kit inhibitor (tyrosine kinase inhibitor) known as masitinib, or AB101. Inhibition of the c-Kit pathway leads to a decrease in histamine levels, mast cells, and IL-4 production, thus decreasing the allergic response. This antineoplastic drug is currently in an international, multicenter, randomized, double-blind, placebo-controlled, three-parallel group Phase IIb/III clinical trial for RA in the US and Czech Republic.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Masitinib (AB101)
For more information visit http://www.researchandmarkets.com/research/gqkcqw/masitinib